Lexicon Pharmaceuticals Unveils Promising Clinical Trial Results for Sotagliflozin, Highlighting Reduced Hypoglycemia Risk in Type 1 Diabetes Patients
Lexicon Pharmaceuticals Inc. announced the results of a post-hoc analysis demonstrating that the addition of sotagliflozin to optimized insulin therapy reduces the risk of clinically important hypoglycemic events in adults with Type 1 Diabetes. These findings were presented at the 85th Scientific Sessions of the American Diabetes Association $(ADA.AU)$ in Chicago, Illinois. The analysis evaluated the effect of kidney function on hypoglycemia risk, using pooled data from inTandem 1 and inTandem 2 Phase 3 clinical trials. The results indicated that sotagliflozin reduces hypoglycemia events, particularly in patients with blood glucose levels ≤55 mg/dL, across various kidney function subgroups without increasing the risk of severe hypoglycemia.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9482320-en) on June 23, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。